Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

Bibliography

• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317-30
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62
   PubMed Web of Science ®Google Scholar
• Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010;10:342-52
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-22
   PubMed Web of Science ®Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of Type-I- and Type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86
   PubMed Web of Science ®Google Scholar
• Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010;70:4260-4
   PubMed Web of Science ®Google Scholar
• Cheng GZ, Zhang W, Wang LH. Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 2008;68:957-60
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene 2012; [Epub ahead of print]
   Google Scholar
• Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 2003;31(Pt 3):573-8
   PubMedGoogle Scholar
• Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-80
   PubMed Web of Science ®Google Scholar
• Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005;19:586-94
   PubMed Web of Science ®Google Scholar
• Chen W, Drakos E, Grammatikakis I, et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer 2010;9:292
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Kaur S, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011;17:4378-88
   PubMed Web of Science ®Google Scholar
• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245-55
   PubMed Web of Science ®Google Scholar
• Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-203
   PubMed Web of Science ®Google Scholar
• Brugarolas J. Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med 2007;356:185-7
   PubMed Web of Science ®Google Scholar
• Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010;7:277-8
   PubMed Web of Science ®Google Scholar
• Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010;10:658-64
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93
   PubMed Web of Science ®Google Scholar
• Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502
   PubMed Web of Science ®Google Scholar
• Livingstone M, Atas E, Meller A, Sonenberg N. Mechanisms governing the control of mRNA translation. Phys Biol 2010;7(2):021001
   PubMedGoogle Scholar
• Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Chantranupong L, Keys HR, et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485:109-13
   PubMed Web of Science ®Google Scholar
• Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Bicohem Sci 2009;34:620-7
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62
   PubMed Web of Science ®Google Scholar
• Menon S MB. Common corruption of the mTOR signaling network in human tumors. Oncogene 2009;27(Suppl 2):S43-51
   Google Scholar
• Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011;23:578-86
   PubMed Web of Science ®Google Scholar
• Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012;32:2-11
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Hypoxia, MTOR and autophagy: converging on senescence or quiescence. Autophagy 2013;9:260-2
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Disc 2011;10:868-80
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009;8:3831-7
   PubMed Web of Science ®Google Scholar
• Gentzler RD, Altman JK, Platanias LC. An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets 2012;16:481-9
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase III trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116:4256-65
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase III study. Lancet 2011;378:2005-12
   PubMed Web of Science ®Google Scholar
• Okuno S, Bailey H, Mahoney MR, et al. A Phase II study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo Phase II consortium (P2C). Cancer 2011;117:3468-75
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012;30:78-84
   PubMed Web of Science ®Google Scholar
• Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527-34
   PubMed Web of Science ®Google Scholar
• Redig AJ, Vakana E, Platanias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leuk Lymphoma 2011;52(Suppl 1):45-53
   PubMed Web of Science ®Google Scholar
• Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101:3130-5
   PubMed Web of Science ®Google Scholar
• Ly C, Arechiga AF, Melo JV, et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716-22
   PubMed Web of Science ®Google Scholar
• Parmar S, Smith J, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFN) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005;106:2436-43
   PubMed Web of Science ®Google Scholar
• Sillaber C, Mayerhofer M, Bohm A, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008;38:43-52
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011;2:510-17
   PubMedGoogle Scholar
• Choo AY, Yoon SO, Kim SG, et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105:17414-19
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010;107:12469-74
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008;5(1):e8
   PubMed Web of Science ®Google Scholar
• Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-82
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Chung YA, Moody G, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337:644-54
   PubMed Web of Science ®Google Scholar
• Dorrello NV, Peschiaroli A, Guardavaccaro D, et al. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006;314:467-71
   PubMed Web of Science ®Google Scholar
• Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2012;119:476-87
   PubMed Web of Science ®Google Scholar
• Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205-13
   PubMed Web of Science ®Google Scholar
• Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009;69:6232-40
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009;421:29-42
   PubMed Web of Science ®Google Scholar
• Willems L, Chapuis N, Puissant A, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012;26:1195-202
   PubMed Web of Science ®Google Scholar
• Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011;118:6860-70
   PubMed Web of Science ®Google Scholar
• Tan DS, Dumez H, Olmos D, et al. First-in-human Phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma [abstract 3006]. J Clin Oncol 2010;28:Suppl ) 15s
   PubMedGoogle Scholar
• Naing A, Aghajanian C, Raymond E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 2012;107:1093-9
   PubMed Web of Science ®Google Scholar
• Banerji U, Dean E, Gonzalez M, et al. First-in-human Phase I trial of the dual mTORC1 and mTORC2 ihibitor AZD2014 in solid tumors [abstract 3004]. J Clin Onc. Presented at American Society of Clinical Oncology Annual Meeting, June 2012
   Google Scholar
• Ghobrial IM, Siegal D, Vij R, et al. MLN0218 (INK128), an Investigational Oral Dual TORC1/2 inhibitor in patients with relapsed or refractory multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): preliminary results from a Phase I dose-escalation study [abstract 4038]. Presented at the American Society of Hematology Meeting, December 2012
   Google Scholar
• NCT01058707. Dose escalation study of INK128 in subjects with advanced cancer. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01058707 [Last accessed 27 November 2012]
   Google Scholar
• NCT01351350. Dose escalation study of INK128 in combination with Paclitaxel, with/without trastuzumab, in subjects with advanced solid malignancies. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01351350 [Last accessed 6 January 2013]
   Google Scholar
• Moroney J, Fu S, Moulder S, et al. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 2012;18:5796-805
   PubMed Web of Science ®Google Scholar
• Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Meadows KL, Uronis HE, et al. A Phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 2012;70:95-102
   PubMed Web of Science ®Google Scholar
• Bullock KE, Petros WP, Younis I, et al. A Phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 2011;67:465-74
   PubMed Web of Science ®Google Scholar